Oncologist

Aims & Scope

The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients.

Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments.

We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	4.2
2024	4.80

SJR (SCImago Journal Rank)

Year	Value
2024	2.329

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	199

Journal Rank

Year	Value
2024	1083

Journal Citation Indicator

Year	Value
2024	4644

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• PubMed
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• SPIKES—A Six-Step Protocol for Delivering Bad News: Application to the Patient with Cancer

  Citation: 2128

  Authors: Walter F., Robert, Renato, Gary, Estela A., Andrzej P.

• FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

  Citation: 1108

  Authors: Bhupinder S., John R., Martin H., Robert, Richard

• Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition

  Citation: 943

  Authors: Gregory A., William, David, Jerome E., Sandra J., Loretta M., David H., Christine, Susan L., Russell K., Nicholas J.

• The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

  Citation: 910

  Authors: Jeffrey S., Elzbieta A., W. Fraser, Lajos, Peter M., Gabriel N.

• The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience

  Citation: 904

  Authors: S. Yousuf, Jeffrey M., Deborah, Donald H., Amy M., Xiaoyin, Amy P.

• Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program

  Citation: 793

  Authors: Matthew J., Nadia, Marsha E., Brenda K.

• Management of Cancer in the Older Person: A Practical Approach

  Citation: 769

  Authors: Lodovico, Martine

• The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

  Citation: 710

  Authors: Alan P., Christos, Junji, Laura

• FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

  Citation: 703

  Authors: Robert Q., Liang, Weishi, Stacy S., Lei, Bahru A., Donna, Ann T., Richard

• Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis

  Citation: 688

  Authors: Dianne, Hermann

---